CPHI Milan 2026
10/2026 – 10/2026
À Propos de l'Entreprise
- Raison sociale: Yuxi Walvax Biotechnology Co., Ltd.
- Pays d'enregistrement: China
- Adresse: 83 South Dongfeng Road, Yuxi • Yunnan
- Nombre d'employés: 1000 - 4999
- Année de création: 2001
Description:
Founded in 2001, Walvax Biotechnology Co. Ltd. is mainly engaged in researching, developing, manufacturing and distributing safe, efficacious human vaccines. A leading publicly listed company in China, Walvax has successfully developed 9 licensed vaccines (13 presentations), including the world's 2nd approved PCV-13 vaccine, 4th approved mRNA COVID-19 vaccine, and 5th approved HPV vaccine.
Activités Commerciales
Produits Biopharmaceutiques
ExportateurFabricant
Classification ATC (Anatomique, Thérapeutique, Chimique)
Fabricant
Marchés de Vente
- South Asia: Bangladesh, India
- Mainland Southeast Asia: Indonesia, Philippines
- Central Asia: Kyrgyzstan, Uzbekistan
- Northern Africa: Egypt, Morocco
- Western Africa: Nigeria, Senegal
Produits/Services Clés
- Produits Biopharmaceutiques: R&D Research and Development, Vaccines, 13-valent pneumococcal conjugate vaccine, Paediatric combination vaccines, Walrinvax meningococcal vaccine
- Classification ATC (Anatomique, Thérapeutique, Chimique): 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Nos Produits & Services
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Proofs
Évaluations
(0)
(0)
(0)
(0)
(0)
Commentaires
Filtres :
Trier par :
Aucun commentaire disponible.
Laissez votre note & commentaire